IL104420A0 - 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents - Google Patents

4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents

Info

Publication number
IL104420A0
IL104420A0 IL104420A IL10442093A IL104420A0 IL 104420 A0 IL104420 A0 IL 104420A0 IL 104420 A IL104420 A IL 104420A IL 10442093 A IL10442093 A IL 10442093A IL 104420 A0 IL104420 A0 IL 104420A0
Authority
IL
Israel
Prior art keywords
formula
nitrogen
group
compounds
optionally substituted
Prior art date
Application number
IL104420A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL104420A0 publication Critical patent/IL104420A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL104420A 1992-01-23 1993-01-18 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents IL104420A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82463992A 1992-01-23 1992-01-23

Publications (1)

Publication Number Publication Date
IL104420A0 true IL104420A0 (en) 1993-05-13

Family

ID=25241935

Family Applications (1)

Application Number Title Priority Date Filing Date
IL104420A IL104420A0 (en) 1992-01-23 1993-01-18 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents

Country Status (16)

Country Link
EP (1) EP0623112B1 (de)
JP (1) JP2668163B2 (de)
KR (1) KR950700284A (de)
AT (1) ATE175196T1 (de)
AU (1) AU3323393A (de)
CA (1) CA2128093C (de)
DE (1) DE69228069T2 (de)
DK (1) DK0623112T3 (de)
ES (1) ES2125325T3 (de)
FI (2) FI930264A (de)
HU (1) HUT63625A (de)
IL (1) IL104420A0 (de)
MX (1) MX9300361A (de)
NO (1) NO942757D0 (de)
WO (1) WO1993015058A1 (de)
ZA (1) ZA93482B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133326A (en) 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
EP1086948A4 (de) * 1998-02-25 2004-03-10 Sumitomo Pharma Pyridonderivate und verfahren zu ihrer herstellung
YU57502A (sh) 2000-02-02 2006-01-16 Warner-Lambert Company Dvojni inhibitori sinteze estara holesterola i estara voska kod poremećaja lojne žlezde
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
AU2005279050A1 (en) * 2004-07-30 2006-03-09 Centre National De La Recherche Scientifique (Cnrs) Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, and the synthesis and uses thereof as antibacterial agents
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ATE116645T1 (de) * 1990-02-10 1995-01-15 Takeda Chemical Industries Ltd Chromenderivate, deren herstellung und verwendung.
CA2108014A1 (en) * 1991-04-26 1992-10-27 Ernest S. Hamanaka 4-aryl-3-(heteroarylureido)quinoline derivatives

Also Published As

Publication number Publication date
HU9300197D0 (en) 1993-04-28
DE69228069T2 (de) 1999-05-20
FI930264A0 (fi) 1993-01-22
ZA93482B (en) 1994-07-22
MX9300361A (es) 1994-06-30
ES2125325T3 (es) 1999-03-01
CA2128093C (en) 1998-02-03
NO942757L (no) 1994-07-22
NO942757D0 (no) 1994-07-22
ATE175196T1 (de) 1999-01-15
CA2128093A1 (en) 1993-08-05
DK0623112T3 (da) 1999-08-30
EP0623112B1 (de) 1998-12-30
JP2668163B2 (ja) 1997-10-27
FI930264A (fi) 1993-07-24
AU3323393A (en) 1993-09-01
HUT63625A (en) 1993-09-28
EP0623112A1 (de) 1994-11-09
DE69228069D1 (de) 1999-02-11
FI20010074A (fi) 2001-01-12
WO1993015058A1 (en) 1993-08-05
KR950700284A (ko) 1995-01-16
JPH07503712A (ja) 1995-04-20

Similar Documents

Publication Publication Date Title
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
EP0703902A4 (de)
AU6876894A (en) New compositions of matter
TW256832B (de)
ZA93482B (en) 4-aryl-3-(heteroarylureido)-1, 2-dihydro-2-oxoquinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
DE69314929T2 (de) Benzolderivate
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents
YU90192A (sh) LANOSTA-7,9-DIEN-3β, 32-DIOL I POSTUPAK ZA NJEGOVO DOBIJANJE,9-DIEN-3BETA, 32-DIOL I POSTUPAK ZA NJEGOVU SINTEZU